HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
HCID 4736Erstellt: 27. Oktober 2026
1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol
Einecs 259-735-2 · VOKSWYLNZZRQPF-UHFFFAOYSA-N · 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol · 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-buten-1-yl)-
https://huagongshe.com/de/chemical/4736
Identifikatoren & physikalische Daten
| CAS No. | 359-83-1 |
|---|
| Summenformel | C19H27NO |
|---|
| Durchschnittliche Molmasse | 285,4 g/mol |
|---|
| Monoisotopische Masse | 285,20926449 g/mol |
|---|
| SMILES | CC(C)=CCN1CCC2(C)c3cc(O)ccc3CC1C2C |
|---|
| InChIKey | VOKSWYLNZZRQPF-UHFFFAOYSA-N |
|---|
| PubChem CID | 4736 |
|---|
| ChEMBL | CHEMBL100116 |
|---|
| ChEBI | CHEBI:182080 |
|---|
| EC No. | 259-735-2 |
|---|
| DTXSID | DTXSID30859346 |
|---|
| Lokaler Name | 1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol |
|---|
Chemische & physikalische Eigenschaften
| XLogP | 3,3 |
|---|
| Polarare Oberfläche (TPSA) | 23,5 |
|---|
| H-Brücken-Donoren | 1 |
|---|
| H-Brücken-Akzeptoren | 2 |
|---|
| Frei drehbare Bindungen | 2 |
|---|
| Schwere Atome | 21 |
|---|
| Formalladung | 0 |
|---|
| Komplexität | 414 |
|---|
| Human Drugs | Breast FeedingLactationMilk, HumanAnalgesics, OpioidNarcoticsNarcotic AntagonistsOpiates |
|---|
| Dissociation Constants | 8.88 |
|---|
| Collision Cross Section | 173.5 Ų [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)] |
|---|
Sicherheit & Vorschriften
| GHS-Einstufung | WarningH302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. |
|---|
| Hazard Classes and Categories | Acute Tox. 4 (100%) |
|---|
| Treatment | Adequate measures to maintain ventilation and general circulatory support should be employed. Assisted or controlled ventilation, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Consideration should be given to gastric lavage and gastric aspiration. For respiratory depression due to overdosage or unusual sensitivity to pentazocine, parenteral naloxone is a specific and effective antagonist. Initial doses of 0.4 to 2.0 mg of naloxone are recommended, repeated at 2-3 minute intervals, if needed, up to a total of 10 mg. Anti |
|---|
| Gesundheitliche Auswirkungen | Medical problems can include congested lungs, liver disease, tetanus, cardiovascular effects, infection of the heart valves, skin abscesses, anemia and pneumonia. Death can occur from overdose. |
|---|
| Expositionspfade | Intravenous, Oral. Well absorbed from the gastro-intestinal tract. |
|---|
| Toxizitätsübersicht | The preponderance of evidence suggests that pentazocine antagonizes the opioid effects by competing for the same receptor sites, especially the opioid mu receptor. |
|---|
| Signs and Symptoms | hallucinations and other psychotomimetic effectscardiovascular effects |
|---|
| Carcinogen Classification | No indication of carcinogenicity to humans (not listed by IARC). |
|---|
| Effects During Pregnancy and Lactation | ◉ Summary of Use during Lactation |
|---|
